STOCKHOLM--(BUSINESS WIRE)--· Group sales reached SEK 5,986 million (6,901). Currency effects and increased competition for the Astelin and Optivar products are the main reasons for lower sales compared to last year. · EBITDA amounted to SEK 2,620 million (2,349), corresponding to a 43.8% margin (34.0).
